Precision NeuroMed Receives FDA Orphan Drug Designation for Glioblastoma Treatment
Thursday, October 09, 2025
Precision NeuroMed (PNM), a clinical-stage biotechnology company developing advanced drug delivery technologies for central nervous system (CNS) disorders, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy targeting glioblastoma multiforme (GBM).
The company is reintroducing cintredekin besudotox (IL13-PE38QQR), a potent cytotoxic protein designed to destroy tumour cells that express the IL-13 alpha-2 receptor (IL13aR), a marker found specifically on glioblastoma cells. This targeted approach enables the therapy to attack cancerous tissue while minimising harm to healthy brain cells.
While significant progress has been made in understanding glioblastoma genetics and potential drug targets, the blood–brain barrier (BBB) remains a major challenge, restricting the delivery of many therapeutic agents to the brain. PNM’s technology uses convection-enhanced delivery (CED) to bypass the BBB, allowing direct and precise administration of nanoparticles such as proteins, liposomes, and gene therapies to the affected brain areas.
Glioblastoma is one of the most aggressive and fatal forms of brain cancer, affecting more than 12,000 people in the United States each year. The average life expectancy after diagnosis is between 12 and 18 months, and the five-year survival rate is approximately 5%. Standard treatment currently involves tumour removal followed by radiation and temozolomide therapy, with no major breakthroughs since temozolomide’s approval in 2005.
PNM aims to advance a personalised treatment strategy that targets both the molecular and regional characteristics of tumour cells. Through improved drug delivery directly to the site of disease, the company seeks to extend survival and improve quality of life for patients with glioblastoma.
The FDA’s Orphan Drug Designation is granted to therapies developed for rare diseases affecting fewer than 200,000 people in the United States. This designation offers incentives such as tax credits for clinical research, exemption from certain FDA fees, and seven years of market exclusivity following approval.
Source: prnewswire.com
